Table 1. Description of sociodemographic and clinical characteristics of the cohort of women enrolled into MTCT-Plus and eligible for incident pregnancy analysis, overall and by age category.
Characteristics | All Participants 4,531 (100%) | Age Category | |||
<25 y, n = 1,373 (30%) | 25–29 y, n = 1,574 (35%) | 30–34 y, n = 1,094 (24%) | 35+ y, n = 484 (11%) | ||
Median years of schooling (y) | 9 | 9 | 9 | 9 | 8 |
Years (y) of education | |||||
0–3 | 602 (13) | 170 (12) | 199 (13) | 153 (14) | 80 (17) |
4–7 | 1,170 (26) | 348 (25) | 369 (23) | 297 (27) | 156 (33) |
8–11 | 1,644 (36) | 572 (42) | 553 (35) | 362 (33) | 157 (32) |
12+ | 1,109 (25) | 283 (21) | 453 (29) | 282 (26) | 91 (19) |
Employed | 1,045 (23) | 195 (14) | 387 (25) | 315 (29) | 148 (31) |
Household electricity | 2,721 (60) | 726 (54) | 1,028 (65) | 680 (63) | 278 (58) |
Household piped water | 1,919 (43) | 535 (39) | 715 (46) | 466 (43) | 203 (42) |
Currently married/cohabiting | 2,929 (66) | 821 (61) | 1,044 (67) | 741 (68) | 323 (70) |
Male partner enrolled into the program | 1,010 (22) | 306 (22) | 368 (23) | 246 (22) | 90 (19) |
Parity: median | 2 | 2 | 2 | 3 | 4 |
Primiparous | 1,013 (22) | 613 (45) | 307 (20) | 88 (8) | 11 (2) |
Estimated travel time to facility (min) | |||||
<30 | 1,623 (36) | 511 (37) | 565 (36) | 375 (34) | 172 (36) |
30–60 | 2,169 (48) | 680 (50) | 736 (47) | 544 (50) | 209 (43) |
60+ | 725 (16) | 179 (13) | 271 (17) | 172 (16) | 103 (21) |
WHO stage at enrollment | |||||
1 | 2,911 (64) | 966 (70) | 1012 (64) | 641 (59) | 292 (60) |
2 | 911 (20) | 262 (19) | 320 (20) | 241 (22) | 88 (18) |
3 | 624 (14) | 127 (9) | 212 (13) | 196 (18) | 89 (18) |
4 | 76 (2) | 17 (1) | 29 (2) | 15 (1) | 15 (3) |
Median CD4 at enrollment (cells/µl) | 366 | 442 | 353 | 322 | 319 |
≥500 | 1,709 (38) | 649 (47) | 568 (36) | 328 (30) | 158 (33) |
350–499 | 863 (19) | 278 (20) | 295 (19) | 207 (19) | 83 (17) |
20–349 | 984 (22) | 256 (19) | 360 (23) | 260 (24) | 108 (22) |
<200 | 975 (22) | 190 (14) | 351 (22) | 299 (27) | 135 (28) |
Initiated ART during follow-up | 1,978 (44) | 461 (34) | 712 (45) | 550 (50) | 255 (53) |